


Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (10-98)
Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/695605
				Filing Date	October 28, 2003
				First Named Inventor	BROUGH, Douglas E.
				Group Art Unit	1636
				Examiner Name	GUZO
Sheet	1	of	2	Attorney Docket Number	224613

U.S. PATENT DOCUMENTS								
Examiner Initials ¹	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Filing Date if Appropriate
		Patent Number	Kind Code					
2	AA	6,127,175		Vigne et al.	10-03-2000	X	X	

FOREIGN PATENT DOCUMENTS										
Examiner Initials ¹	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Translation	
		Office	Number	Kind Code					Yes	No*
2	AB	FR	2705686	A	Transgene S.A.	12-02-1994	X	X		
2	AC	WO	01/44280	A	Genovo, Inc.	06-21-2001	X	X		


OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No*	
2	AD	BERNARDS et al., <i>Virology</i> , 150 (1), 126-139 (April 15, 1986). ✓			
2	AE	BROUGH et al., <i>J. Virol.</i> , 70 (9), 6497-6501 (September 1996).			
2	AF	CHIOU et al., <i>J. Virol.</i> , 68 (10), 6553-6566 (October 1994).			
2	AG	ENGELHARDT et al., <i>Hum. Gene Ther.</i> , 5, 1217-1229 (October 1994).			
2	AH	GOLDSMITH et al., <i>Virology</i> , 248 (2), 406-419 (September 1, 1998).			
2	AI	GOODRUM et al., <i>J. Virol.</i> , 72 (12), 9479-9490 (December 1998).			
2	AJ	HARADA et al., <i>J. Virol.</i> , 73 (7), 5333-5344 (July 1999).			
2	AK	HAY et al., <i>Hum. Gene Ther.</i> , 10, 579-590 (March 1, 1999).			
2	AL	HORVATH et al., <i>Virology</i> , 184 (1), 141-148 (September 1991). ✓			

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	2/14/05
--------------------	---	-----------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/695605
				Filing Date	October 28, 2003
				First Named Inventor	BROUGH, Douglas E.
				Group Art Unit	1636
				Examiner Name	GUZO
Sheet	2	of	2	Attorney Docket Number	224613

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation		
			Yes	No*	
JL	AM	IMPERIALE et al., <i>Mol. Cell Biol.</i> , 4 (5), 867-874 (May 1984).			
OT	AN	KIMURA et al., <i>Tumor Res.</i> , 32, 1-21 (1997).			
OT	AO	KOVESDI et al., <i>Cell</i> , 45, 219-228 (April 25, 1986).			
OT	AP	La THANGUE et al., <i>Cell</i> , 49, 507-513 (May 22, 1987).			
OT	AQ	La THANGUE et al., <i>Nucl. Acids Res.</i> , 18 (10), 2929-2938 (May 25, 1990).			
OT	AR	LEE et al., <i>Int. J. Cancer</i> , 88 (3) 454-463 (November 1, 2000).			
OT	AS	RAO et al., <i>PNAS USA</i> , 89, 7742-7746 (August 1992).			
OT	AT	RIES et al., <i>Nat. Med.</i> , 6 (10), 1128-1133 (October 2000).			
OT	AU	SHAW et al., <i>FASEB J.</i> , Express Article 10.1096/fj.01-0995fje (April 10, 2002).			
OT	AV	SPECTOR et al., <i>Virology</i> , 151 (2), 329-338 (June 1986).			
OT	AW	SPERGEL et al., <i>PNAS USA</i> , 88, 6472-6476 (August 1991).			
OT	AX	SPERGEL et al., <i>J. Virol.</i> , 66 (2), 1021-1030 (February 1992). ✓			
OT	AY	TEVETHIA et al., <i>Virology</i> , 161 (2), 276-285 (December 1987).			
OT	AZ	TREMBLAY et al., <i>Virology</i> , 144 (1), 35-45 (July 15, 1985).			
OT	BA	WILKINSON et al., <i>Nucl. Acids Res.</i> , 20 (9), 2233-2239 (May 11, 1992).			
OT	BB	YANG et al., <i>PNAS USA</i> , 91, 4407-4411 (May 1994).			

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	David Suger	Date Considered	2/14/05
-----------------------	-------------	--------------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.